A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2017
At a glance
- Drugs Stapuldencel-T (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms VIABLE
- Sponsors SOTIO
- 06 Nov 2017 According to a SOTIO media release, data on the overall survival of patients in this study are expected in 2020.
- 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated